China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D